Other
Immunosuppression reduction
Immunosuppression reduction is an intervention with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_4
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Recruiting1
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
recruiting133%
unknown133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingnot_applicable
Fibroscan to Guide Post Transplant Immunosuppression Minimization
NCT07206277
completedphase_4
Immune Monitoring to Facilitate Belatacept Monotherapy
NCT04177095
unknownphase_1
Pilot Trial on Immunosuppression Modulation to Increase SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients
NCT05338177
Clinical Trials (3)
Showing 3 of 3 trials
NCT07206277Not Applicable
Fibroscan to Guide Post Transplant Immunosuppression Minimization
NCT04177095Phase 4
Immune Monitoring to Facilitate Belatacept Monotherapy
NCT05338177Phase 1
Pilot Trial on Immunosuppression Modulation to Increase SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients
All 3 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 3